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Abstract
As a master regulator of chromatin function, the lysine methyltransferase EZH2 orchestrates 
transcriptional silencing of developmental gene networks. Overexpression of EZH2 is commonly 
observed in human epithelial cancers, such as non-small cell lung carcinoma (NSCLC), yet 
definitive demonstration of malignant transformation by deregulated EZH2 remains elusive. Here, 
we demonstrate the causal role of EZH2 overexpression in NSCLC with new genetically-
engineered mouse models of lung adenocarcinoma. Deregulated EZH2 silences normal 
developmental pathways leading to epigenetic transformation independent from canonical growth 
factor pathway activation. As such, tumors feature a transcriptional program distinct from KRAS- 
and EGFR-mutant mouse lung cancers, but shared with human lung adenocarcinomas exhibiting 
high EZH2 expression. To target EZH2-dependent cancers, we developed a novel and potent 
EZH2 inhibitor JQEZ5 that promoted the regression of EZH2-driven tumors in vivo, confirming 
oncogenic addiction to EZH2 in established tumors and providing the rationale for epigenetic 
therapy in a subset of lung cancer.
Keywords
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Introduction
Lung cancer is the most common and one of the most deadly cancers worldwide (1). Non-
small cell lung cancers (NSCLC) are the most prevalent type of lung cancer, comprising a 
heterogeneous set of diseases (2). The identification of recurrent mutations and 
amplifications in many targetable oncogenes has significantly improved overall survival of 
subsets of NSCLC patients. Activating mutations in BRAF, KRAS and the epidermal 
growth factor receptor (EGFR), as well as fusions involving anaplastic lymphoma kinase 
(ALK), have been associated with response to kinase inhibition (3–6). Furthermore, with the 
advent of improved genomic profiling and next-generation sequencing, recurrent mutations 
and amplifications have been identified in HER2, MET, fibroblast growth factor receptor 1 
(FGFR1) and FGFR2, the ROS1 receptor tyrosine kinase, neuregulin 1 (NRG1), 
neurotrophic tyrosine kinase receptor type 1 (NTRK1) and RET (2). While together these 
alterations account for many cases of lung adenocarcinoma, a considerable population of 
NSCLC patients lacks identifiable genetic lesions in therapeutically tractable targets.
Beyond growth factor signaling pathways, chromatin-associated complexes have recently 
been identified as recurrently altered or transcriptionally deregulated in NSCLC, including 
TET methylcytosine dioxygenase 2 (TET2), DNA methyltransferase 3A (DNMT3A) and 
enhancer of zeste homologue 2 (EZH2) (7). Notably, each of these factors influences 
heterochromatin structure, and has been linked to coordinated regulation of normal 
developmental transcriptional pathways (8–11). These data establish the hypothesis that 
disruption of chromatin architecture is a common event in lung cancer pathogenesis, either 
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permissive with or distinct from oncogenic signaling pathways, functioning to deregulate 
transcriptional programs associated with cellular differentiation.
The dynamic structure of chromatin is influenced by post-translational modifications 
(PTMs) to DNA and to the unstructured amino-terminal tails of histone proteins within 
nucleosomal particles. Control of gene expression pathways by DNA-binding transcriptional 
activators and repressors influences the recruitment of chromatin-associated enzyme 
complexes that confer covalent PTMs to chromatin. In general, side-chain acetylation of 
lysine residues on histone tails is associated with active, euchromatin, notably at histone 3 
lysine 27 as associated with active cis-regulatory enhancer elements (H3K27ac) (12). 
Modification of H3K27 exhibits switch-like behavior, as mono-, di- and tri-methylation of 
H3K27 (H3K27me1, -me2, -me3) is associated with repressive, facultative heterochromatin 
(13). H3K27 methylation is principally mediated by the polycomb group repressive complex 
2 (PRC2), a multi-protein assembly that activates and directs the function of a core catalytic 
enzyme EZH2 mediating S-adenosyl methionine dependent lysine methylation.
Recurrent alteration of EZH2 is observed in solid and hematologic malignancies, 
underscoring the unexpected centrality of chromatin structure in the pathogenesis of cancer. 
Interestingly, both activation (recurrent mutation, overexpression) and inactivation 
(deletions, inactivating mutations) of EZH2 have been characterized, supporting a tissue-
specific role for EZH2 as either an oncogene or tumor suppressor. EZH2 activating 
mutations have been characterized in B-cell lymphoma (14, 15). More broadly than these 
focused genetic events, over-expression of EZH2 is found in a wide range of cancers (16, 
17). While overexpression is associated with increased global H3K27me3, prompts silencing 
of tumor suppressors and developmental regulators and often confers a poor prognosis, it 
can also restrain tumorigenesis in specific epithelial contexts (18–21). Of relevance to lung 
adenocarcinoma, several recent studies reproducibly demonstrated a correlation between 
increased EZH2 expression and poor outcome (22–24).
EZH2 has thus emerged as a pressing target for cancer therapeutic development. Strategies 
have been undertaken to develop disruptors of complex assembly (25), as well as SAM-
competitive inhibitors of the canonical SET lysine methyltransferase domain (26–28). 
Selective EZH2 inhibition using these chemical probes has established EZH2 as a context-
specific tumor dependency while providing pharmacologic target validation in B-cell 
lymphoma (26–28) and defined soft-tissue sarcomas (29, 30). Accordingly, human clinical 
investigation has been initiated using drug-like EZH2 inhibitors (ClinicalTrial.gov identifier: 
NCT01897571, NCT02082977, NCT02395601, NCT02601937, NCT02601950).
The evident overexpression of EZH2 in lung adenocarcinoma and the feasibility of clinical 
investigation motivated the present effort to characterize the effect of transcriptional 
deregulation of EZH2 on lung cancer pathogenesis. Using genetic and chemical genetic 
approaches, we demonstrate for the first time an oncogenic role for wild-type EZH2 
overexpression in lung cancer and the opportunity for epigenomic therapy in this disease. 
Specifically, we generated genetically-engineered mouse models (GEMMs) overexpressing 
wild-type human EZH2 systemically and specifically in lung. We show that EZH2 
overexpression promotes the formation of lung tumors that exhibit biochemical and 
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transcriptional features akin to the subset of human tumors that express high levels of EZH2. 
Analysis of chromatin state in EZH2 overexpressing lung tumors revealed the aberrant 
spread of H3K27me3 notably at developmental regulator gene loci, many of which are 
known tumor suppressors in lung cancer. To overcome limitations in potency, availability 
and in vivo utility of current EZH2 inhibitors, we developed and characterized a novel and 
open-source EZH2 chemical probe, JQEZ5. In GEMM and human NSCLC models, JQEZ5 
exhibits excellent exposure and pharmacodynamic target modulation. Long-term treatment 
of EZH2-addicted, tumor-bearing mice with JQEZ5 uniformly led to decreases in tumor 
burden. Together, these studies reveal a role for EZH2 as a NSCLC driver gene and an 
opportunity for targeted epigenomic therapy.
Results
EZH2 overexpression causes murine lung cancer
To investigate the causal role of EZH2 overexpression in cancer, we ubiquitously enforced 
EZH2 expression in the mouse using two different strategies to control for temporal 
specificity. All mice were engineered to carry one copy of a transgene expressing full-length 
human EZH2 containing a STOP cassette flanked by loxP sites between the CAG promoter 
and the EZH2 gene (LSL-EZH2) (Supplementary Figure S1A–B). We utilized two different 
strategies to induce EZH2 overexpression using Cre recombinase (Figure 1A). First, Actin-
Cre was used to constitutively overexpress EZH2 in all tissues of the mouse (Actin-
Cre:LSL-EZH2). Secondly, Ubiquitin-Cre-ERT2 (UBC:LSL-EZH2) was used to 
ubiquitously overexpress EZH2 upon treatment with tamoxifen at 6 weeks of age.
Actin-Cre:LSL-EZH2 mice overexpressed EZH2 as demonstrated by both 
immunohistochemistry (IHC) and Western blotting (Supplementary Figure S1C–D). These 
animals were viable, fertile, developmentally normal, and indistinguishable from their 
littermates that did not express Cre recombinase through adulthood (data not shown). Thus, 
overexpression of EZH2 is tolerable during embryonic and developmental growth. As the 
Actin-Cre:LSL-EZH2 mice entered adulthood, multiple tumor types were observed 
including lymphoma, histiocytic sarcoma of the liver and lung adenomas/adenocarcinomas. 
Half of the mice developed lung adenomas/adenocarcinomas without apparent metastases 
(Supplementary Table S1–2). Likewise, UBC:LSL-EZH2 mice that were administered 
tamoxifen at 6 weeks of age also developed lung adenocarcinomas with 40% penetrance. As 
expected, wild-type mice had no evident phenotype and all harvested lungs were normal at 
80 weeks, suggesting a causal role of EZH2 overexpression in lung tumorigenesis. To extend 
these findings, we restricted EZH2 overexpression to lung in a third GEMM using inhaled 
Adeno-Cre virus to direct Cre expression to the pulmonary epithelium of LSL-EZH2 mice 
(Figure 1A) (31). Adeno-Cre was administered to animals at 6-weeks of age and 42% of 
these animals developed lung adenocarcinoma, demonstrating that EZH2 overexpression in 
lung epithelial cells is sufficient to induce cancer. In sum, our data demonstrate that 45% of 
EZH2-overexpressing mice develop lung adenocarcinomas with an average survival to 73.6 
weeks of age (Figure 1B).
The histology of mouse lung tumors demonstrated features of human grade 1–2 lung 
adenoma/adenocarcinoma. As compared to normal mouse lung, EZH2-overexpressing lung 
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adenocarcinomas showed high cellularity and less differentiation, all consistent with low- 
and intermediate-grade adenocarcinoma (Figure 1C). IHC analysis of tumors arising from 
EZH2 overexpression demonstrated an increase in the proliferative marker, Ki67, as 
compared to normal lung tissue (Figure 1C). In a comparison to murine lung cancers driven 
by expression of activated KRAS (KRASG12D), EZH2 expression was markedly higher in 
the EZH2-driven lung tumors (Figure 1D). Analysis for the expression of pathway markers 
typically identified in KRAS-driven lung cancer, such as phosphorylated AKT (p-AKT) and 
phosphorylated ERK (p-ERK), revealed low p-AKT and p-ERK expression in EZH2-
induced mouse lung tumors (Figure 1D). Western blot analysis further confirmed that EZH2 
mouse lung tumors have significantly less p-AKT and p-ERK than both KRAS-induced 
mouse lung tumors and normal mouse lung (Figure 1E and Supplementary Figure S1E). 
Taken together, these data suggest that lung tumors driven by EZH2-mediated epigenomic 
deregulation are histologically similar but molecularly distinct from lung tumors driven by 
KRAS-dependent oncogenic signaling.
As KRAS and EZH2 expression are not mutually exclusive (Figure 1D), we wanted to 
explore possible synergy between KRAS and EZH2 in lung tumorigenesis. KRASG12D 
(LSL-KRAS) was introduced into the lung epithelium with or without EZH2 overexpression 
(+/− LSL-EZH2) via inhalation of viral Adeno-Cre. Six weeks post induction, LSL-KRAS 
and LSL-KRAS;LSL-EZH2 mice had comparable tumors with comparable morphology, 
even though EZH2 overexpression was only evident in the LSL-KRAS;LSL-EZH2 mice 
(Figure 1F). Significantly, we did not observe an increase in tumorigenesis or a decrease in 
survival in the presence of EZH2 overexpression (Figure 1G), suggesting that EZH2 
overexpression does not modify tumorigenesis driven by the KRAS oncogene.
EZH2-driven lung cancer as a molecularly distinct entity
To dissect the molecular features of EZH2-induced mouse lung cancer, we first performed 
RNA sequencing (RNA-seq) to compare the gene expression profiles of EZH2-
overexpressing pre-cancerous normal lung tissue and EZH2-overexpressing lung 
adenocarcinoma tumors from mice (Supplementary Table S3). Using unsupervised 
hierarchical clustering, gene expression profiles from these samples were compared to 
expression profiles of EGFR-mutated and KRAS-mutated lung adenocarcinoma mouse 
tumors (Figure 2A). EZH2-overexpressing tumors segregated as transcriptionally distinct 
from EZH2-overexpressing normal lung, EGFR- and KRAS-mutated lung tumors. These 
data suggest that EZH2 modulation of chromatin leads to alteration of transcriptional 
pathways distinct from canonical lung adenocarcinomas driven by EGFR and KRAS 
hyperactivating mutations. Additionally, analysis of RNA-Seq data for secondary driver 
mutations revealed that there are no recurrent somatic alterations in the coding portion of 
expressed known driver oncogenes or tumor repressors in murine EZH2-overexpressing 
tumors (data not shown).
Having defined an EZH2-dependent, tumor-specific transcriptional state in murine lung 
adenocarcinoma, we next assessed whether a comparable subset of human NSCLC exists. 
Using publicly available data from The Cancer Genome Atlas (TCGA), we identified a 
cohort of lung adenocarcinoma patients with elevated tumor EZH2 expression 
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(Supplementary Figure S2A). Nearly all lung tumors overexpress EZH2 as compared to 
normal tissue. EZH2 expression in human lung cancer was found to be broadly distributed 
over a >50-fold range and high EZH2 levels were not mutually exclusive with KRAS or 
EGFR mutations. In tumors with the highest EZH2 expression (mean + 2 SD, 28 tumors), 
21% harbor canonical “driver mutations” (e.g. EGFR and KRAS) whereas 43% of tumors 
harbored these mutations in the overall dataset (230 tumors). We further selected highly 
EZH2-overexpressing tumors (top 20%) with wild-type KRAS and EGFR to emulate the 
genetics of our murine models. Pathway enrichment was assessed by Gene Set Enrichment 
Analysis (GSEA) (32, 33). Transcriptional signatures associated with MEK and mTOR 
activation were repressed in EZH2-overexpressing tumors as compared to tumors with low 
EZH2 expression regardless of the presence or absence of oncogenic KRAS or EGFR 
mutations (Figure 2B), corroborating again that EZH2 driven tumors are molecularly distinct 
from tumors driven by canonical signaling pathways.
Influence of EZH2 overexpression on chromatin structure in murine lung cancer
To understand the dynamic effects of EZH2 overexpression on chromatin structure in the 
context of malignant transformation, we performed comparative epigenomic analysis of 
normal and malignant murine lung tissues. We and others have used genome-wide 
assessment of enhancer-promoter activity, measured by H3K27ac chromatin 
immunoprecipitation with massively parallel DNA sequencing (ChIP-seq), to comparatively 
study malignant and inflammatory cell states (34, 35). Focusing epigenomic analysis on 
regions of massive H3K27ac enrichment, so-called super enhancers (SEs), has afforded 
inferences into oncogenic signaling (36) and the sub-classification of human tumors (34). 
Therefore, we first mapped active enhancers across the three tissue types by H3K27ac ChIP-
seq, and identified regions of differential hyperacetylation (SEs), as we previously reported 
(34, 37). Unsupervised hierarchical clustering segregated murine tumor (KRAS- and EZH2-
driven tumors) and pulmonary tissue (WT), demonstrates a distinct euchromatin epigenome 
structure (Supplementary Figure S2B). Differential analysis of highly occupied H3K27ac 
regions in EZH2-overexpressing tumors and normal lung revealed global redistribution of 
H3K27ac, with 771 individual loci exhibiting a greater than log2 1.5-fold change in 
H3K27ac (Figure 2C, left). The same analysis between EZH2-overexpressing and KRAS-
driven tumors also revealed a distinct redistribution of H3K27ac, with 317 individual loci 
exhibiting a greater than log2 1.5-fold change in H3K27ac (Figure 2C, right).
Differences in gene expression and the SE signatures upon EZH2 overexpression versus 
KRAS-driven transformation in mice may be due to changes in the activated signaling 
molecules leading to modulation of different transcription factor (TF) networks. To identify 
TFs responsible for the gene expression changes and SE signatures upon EZH2 versus 
KRAS transformation, we identified TF binding sites enriched at SEs activated upon 
transformation. We constructed an SE-defined transcriptional network for normal and 
tumorigenic cell states by integrating maps of SE-associated master TFs with TF binding 
site data to reconstruct the core transcriptional regulatory circuitry (38). Our analysis defines 
three independent core transcriptional regulatory circuitries, which further underscores the 
mechanistically unique tumorigenic activity of EZH2 versus KRAS (Figure 2D). Thus, we 
have further established a unique signature of EZH2-overexpressing murine lung tumors, 
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which exhibit divergent core circuitries where deregulated master TFs are enforced by a 
unique network of super-enhancer associated TFs.
Influence of super enhancers on gene expression in EZH2-overexpressing lung cancer
To determine whether changes in H3K27ac at SEs resulted in reciprocal changes in gene 
expression at adjacent expressed genes, we analyzed RNA-seq data from WT and EZH2-
overexpressing murine tumors and found that the modulation of chromatin impacted gene 
expression in these tumors (Figure 3A). Unbiased leading edge analysis of genes proximal 
to regions of lost H3K27ac in murine tumors identified polycomb repressive target gene 
signatures, implicating PRC2-mediated repression of these regulatory elements (Figure 
3B,C).
To link EZH2 function to lost SEs, we next performed H3K27me3 ChIP-seq on WT and 
EZH2-overexpressing mouse samples. Among regions of lost H3K27ac SEs, we identified a 
distinct subgroup of 33 cis-regulatory regions where loss of H3K27ac was accompanied by 
strong gain of the polycomb H3K27me3 mark (Figure 3D). Functionally, 32 genes 
associated with these 33 regulatory regions showed decreased gene expression in murine 
tumors by RNA-seq (Figure 3E), and were comprised of numerous developmental 
transcriptional regulators, including Foxf1a, Irf8, Hoxa9, and Meis1, as well as other 
chromatin factors such as Aff3 (Figure 3F). Repression of Hoxa9, Meis1, Irf8, and Foxf1 
have been observed in NSCLC, and their activity has been functionally linked to decreased 
tumorigenesis, suggesting a tumor suppressive role for these gene regulator (39, 40). Visual 
inspection of master developmental TFs repressed in tumor samples confirmed an 
epigenomic switch from large hyperacetylated enhancer elements to broad regions of 
H3K27 trimethylation, (Supplementary Figure S2C–E).
Among the gained SE-associated regions in murine tumor samples, notably, were genes 
encoding well-characterized, negative regulators of the MAPK-ERK pathway: Dusp4, 
Spry1, Spry2 and Errfi1 (Figure 2C, left). Visual inspection corroborated that all four genes 
featured robust gain in H3K27ac at cis-regulatory elements (Figure 3G–H), and RNA-seq 
confirmed elevated expression in tumors. These data identify enhancer remodeling 
attributable to overexpressed EZH2 in the progression to lung adenocarcinoma, specifically 
silencing normal differentiation genes and activating negative regulators of MAPK-ERK 
signaling consistent with the signal transduction immunophenotyping of the EZH2-driven 
GEMMs.
To explore the relevance of these findings to human lung cancer pathophysiology, we next 
asked whether downregulation of the PRC2 hypermethylated, SE-associated genes identified 
in murine tumors is observed in EZH2-overexpressing human lung adenocarcinoma. Indeed, 
strong downregulation of the functional, 32 gene set is observed in human lung cancers with 
the highest (top 20%) expression of EZH2 and not in normal lung or tumors driven by 
KRAS or EGFR (Figure 3I). Taken together, integrated epigenomic analysis argues that 
there is a distinct subset of human lung cancers that are characterized by 1) high levels of 
EZH2, 2) low activation of Ras effectors, and 3) suppression of a distinct set of EZH2 target 
genes.
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Human NSCLC with high EZH2 expression is sensitive to EZH2 depletion
To examine the oncogenic potential of EZH2 in human cells, we overexpressed EZH2 in an 
immortalized normal human lung epithelial cell line (hTBE) and monitored oncogenic 
potential (Supplementary Figure S3A). EZH2-overexpressing hTBE cells (oeEZH2) formed 
colonies on soft agar and acquired higher transformation capacity over time (serial passages) 
as compared to control cells (Supplementary Figure S3B–C). Differential SE landscape 
analysis from hTBE and hTBE-oeEZH2 cells illustrates a significant gain and loss of SEs 
when EZH2 is overexpressed (Supplementary Figure S3D). These data demonstrate that 
overexpressing EZH2 modifies the SE landscape as a primary effect of its overexpression in 
human cells.
The observation that EZH2 overexpression produces lung cancer in mice and transforms 
normal human lung epithelia cells suggests that EZH2 may play an essential role in a subset 
of human NSCLCs. Using two previously verified EZH2 shRNAs, we knocked down EZH2 
expression in a panel of rare, human oncogene wild-type NSCLC cell lines (41–43). Both 
shRNAs showed nearly complete inhibition of EZH2 protein expression as compared to cells 
with a non-targeting shRNA control (Figure 4A). Cell proliferation assays revealed that 
H522 and H661 cells, which express high levels of EZH2 with no other known oncogenic 
mutations, displayed more than 50% growth inhibition in response to EZH2 knockdown 
compared to control cells (Figure 4B–C, Supplementary Figure S3E). Growth of human 
NSCLC cell lines expressing slightly lower levels of EZH2, namely H292, H969, H2250, 
and H2258 cells, were largely unaffected by knockdown of EZH2 (Figure 4B,D, 
Supplementary Figure S3E–F). Finally, we tested whether EZH2 expression was required 
for tumor formation in mouse xenograft models of human NSCLC. H661 and H292 cells 
expressing either control or shEZH2 vectors were injected subcutaneously into mice and 
tumor formation was monitored bi-weekly. EZH2 knockdown significantly inhibited growth 
of H661 tumors in vivo while having no effect on H292 tumor formation (Figure 4E, F). 
Therefore, we identified human lung cancer cell lines that are oncogene wildtype and highly 
dependent on EZH2 overexpression.
Dependency of EZH2-overexpressing lung cancer on catalytically active EZH2
To assess the dependency of EZH2-overexpressing lung tumors on sustained EZH2 
enzymatic activity, we employed a chemical genetic approach. Recently, several pyridinone-
based small molecule inhibitors of EZH2 were reported as chemical probes (e.g. GSK-126, 
UNC1999 and EPZ-6438; Supplementary Figure S4A) (28, 44, 45). Both of these near 
structural analogues are potent and selective inhibitors of EZH2, however the broader utility 
of these probes in biological research in vivo may be limited by low potency (high dose 
administration), limited bioavailability (twice daily dosing), and uncertain availability (cost 
of synthesis, pharmaceutical material transfer, undisclosed structure of EPZ-6438 while we 
conducted these studies). We therefore undertook to develop a novel EZH2 inhibitor as an 
open-source chemical probe for the scientific community. Lacking the guidance of 
crystallographic data, structure-activity relationships were deduced empirically from 
iterative analogue synthesis and biochemical testing.
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Emerging from follow-up chemistry is JQEZ5, which features a pyrazolo-pyridine core 
displaying a 6-substituted solubilizing feature and a preserved pyridinone warhead 
(highlighted in red; Figure 5A). The synthesis of JQEZ5 is nine linear steps, high-yielding 
and scalable (see Supplementary Methods), to support broad distribution. As a paired 
control, we developed JQEZ23 with the substitution of the active pyridinone to a predicted 
inactive pyridinium ring (highlighted in blue; Figure 5A). Both compounds were evaluated 
in enzymatic assays with a five-component PRC2 complex with radiometric labeled S-
adenosyl methionine (SAM). JQEZ5 inhibited enzymatic functionality of PRC2 with a 
biochemical IC50 of 80nM, similar to GSK-126 and UNC1999, while JQEZ23 had little 
inhibitory activity towards purified PRC2 (Figure 5B, Supplementary Figure S4B). JQEZ5 
exhibited SAM-competitive inhibition of PRC2, as determined by biochemical inhibition 
assessed in the presence of escalating unlabeled SAM co-factor concentration (Figure 5C, 
Supplementary Figure S4C). To understand the putative mode of molecular recognition of 
EZH2 by our inhibitor, we modeled binding of JQEZ5 to EZH2 using a recently reported 
computational model (Figure 5D) (46). The binding model we established indicates that the 
D-pyridinone ring of JQEZ5 binds to Asn78 on EZH2, and that the pyrazolo-pyridine ring 
is deeply buried in the SAM-binding pocket of EZH2. The ligand interaction diagram (LID) 
of JQEZ5 and EZH2 (Supplementary Figure S4D) also predicts that the piperazine ring on 
JQEZ5 extends out of the SAM-binding pocket of EZH2 and is thus, amenable to further 
modification. Based on this prediction, we appended a biotin tag to the piperazine ring of 
JQEZ5 to create JQEZ6 (Supplementary Figure S4E). Using surface plasma resonance 
(SPR), we measured the binding affinity of the five-component PRC2 complex for JQEZ6 
immobilized on a streptavidin chip surface. The binding affinity measured by SPR (87.0nM) 
is similar to other biochemical assays that we performed (Figure 5E). Negative control 
compounds (ex. biotinylated-JQ1) did not exhibit binding to the PRC2 complex (data not 
shown), further demonstrating the specificity of JQEZ6 for the PRC2 complex. Finally, the 
specificity of JQEZ5 for EZH2 was confirmed via an orthogonal study of a panel of 22 
recombinant, purified lysine methyltransferases (Reaction Biology, Supplementary Figure 
S4F) (47).
After biochemically validating the specificity and potency of JQEZ5, we treated human 
oncogene wild-type NSCLC cells in dose-ranging biochemical and cellular studies. H661 
cells treated with increasing concentrations of JQEZ5 demonstrated acutely reduced levels 
of H3K27me3 without affecting H3K27 mono- or di-methylation, as assessed by Western 
blotting (Figure 6A). Treatment had no affect on H3K27me3 levels in the non-sensitive 
H292 human NSCLC cell line. Treatment with the negative control compound, JQEZ23, 
did not have any effect on H3K27 methylation or acetylation status (Figure 6B). H3K27me3 
reduction correlated with compound concentration as well as length of treatment (Figure 
6C). Similar to our EZH2 shRNA studies, JQEZ5 suppressed the proliferation of EZH2-
overexpressing H661 and H522 cells after treatment for 4 days without affecting the 
proliferation of cell lines that were deemed insensitive to EZH2 knockdown (Figure 6D–E, 
Supplementary Figure S5A–B). In a direct comparison to alternate SAM-competitive EZH2 
inhibitors, JQEZ5 inhibited cell growth more effectively that GSK-126 and GSK-343 in the 
H522 cell line (Supplementary Figure S5B). Finally, shRNA knockdown of EZH2 in H661 
cells rendered cells insensitive to JQEZ5-induced cell growth arrest (Figure 6F). Together, 
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these data demonstrate the limited off-target activity of the chemical probe and support the 
notion that JQEZ5 is effectively targeting EZH2 in human lung cancer cell lines.
JQEZ5 inhibits tumor growth in EZH2-overexpressed lung cancer
To further explore the translational relevance of this research, we undertook therapeutic 
trials of JQEZ5 in tumor-bearing GEMMs. JQEZ5 was formulated for intraperitoneal (IP) 
administration and repeat dosing studies established 75 mg/kg IP daily as a tolerated dose 
and schedule with no observed toxicities (Supplementary Figure S5C). Pharmacokinetic 
studies confirmed excellent exposure to JQEZ5 without the need for twice daily dosing 
(Supplementary Figure S5D). To prepare for therapeutic studies, Actin-Cre:LSL-EZH2 mice 
and UBC:LSL-EZH2 mice (treated with tamoxifen at 6 weeks of age) were monitored 
weekly for the onset of symptoms of lung adenocarcinoma (breath distress). At that time 
(t=0), lung cancers were visualized and confirmed by MRI (Figure 7A, B). Tumor-bearing 
mice were then treated with JQEZ5 for three weeks (75 mg/kg IP daily) and the tumor 
volume of the lungs was comparatively visualized by MRI. Animals treated with JQEZ5 
exhibited rapid and pronounced tumor regression over the three week treatment course, as 
demonstrated by two-dimensional MRI and volumetric measurements (Figure 7C). 
Additionally, H3K27me3 levels were largely reduced with treatment further confirming the 
on-target effect of JQEZ5 in mice (Figure 7D). To model the therapeutic opportunity of 
EZH2 inhibition in vivo, we evaluated the tolerability and anti-tumor efficacy of JQEZ5 in a 
murine xenograft model of human NSCLC cells (H661 cells). Tumor-bearing mice were 
treated with JQEZ5 administered by intraperitoneal injection (75 mg/kg daily) or vehicle 
control for 18 days. Administration of JQEZ5 was well tolerated. The level of H3K27me3 
was largely reduced with the treatment without effect on EZH2 levels in both the tumor 
(Figure 7E) and in the lung tissue of treated animals (Figure 7F). More importantly, JQEZ5 
treatment attenuated tumor progression as determined by serial volumetric measurement 
(Figure 7G) to further confirm the therapeutic potential of EZH2 inhibitors in this subset 
human lung cancer.
Discussion
As the leading cause of death from cancer, lung cancer comprises a profound unmet medical 
need. A subset of lung cancer patients have benefited from targeted therapies in the past 
decade, yet the majority of patients will not benefit from these approaches and all metastatic 
disease remains incurable. There exist a large number of patients who cannot be effectively 
treated due to the lack of druggable oncogenic drivers (e.g. KRAS). As such, discovering 
new actionable drivers and tumor dependencies in these remaining tumors is an urgent and 
important endeavor.
Though not affected by somatic alteration, deregulated overexpression of EZH2 is observed 
in a subset of human lung cancers (22–24). To date, a causal role in lung tumor development 
has not been established. In this study, we explored the oncogenic potential of EZH2 
deregulation by generating a series of genetically engineered mouse models with conditional 
EZH2 overexpression. Three GEMMs establish evident oncogenic activity for EZH2 in 
NSCLC formation. Indeed, 45% of mice engineered to overexpress EZH2 developed lung 
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adenocarcinomas. These tumors lacked recurrent somatic mutations in in known driver 
oncogenes and tumor suppressors and EZH2 overexpression had no effect on KRAS-mutant 
lung tumor formation, demonstrating that EZH2 has weak, but apparent oncogenic activity 
in lung. These data resonate with prior studies that exemplified the transforming activity of 
mutant EZH2 in B-cell lymphoma (14, 15). A prior study showed that EZH2 overexpression 
in the myeloid compartment elaborated a myeloproliferative disorder, but to date firm 
evidence of neoplastic transformation by EZH2 overexpression has been elusive (48). EZH2 
expression has even been shown to restrain tumorigenesis in some epithelial cancer models 
(21). To our knowledge, this work is a first demonstration of cancer resulting from wild-type 
EZH2 overexpression in vivo. Overexpression of EZH2 is, again, a common feature of 
numerous solid tumors, and the reagents created in this study will be helpful to further 
define the role of EZH2 in the pathogenesis of cancer more broadly in different contexts.
Cell biology studies and integrated epigenomic analysis of the resultant EZH2-driven murine 
tumors emulate the cytosolic and transcriptional signaling of a defined subset of the human 
disease. Interestingly, lung adenocarcinomas induced by EZH2 overexpression displayed 
low levels of p-AKT and p-ERK, which are accompanied by elevated expressions of known 
negative regulators of the MAPK-ERK pathway such as dual-specificity protein phosphatase 
4 (DUSP4) and sprouty homologs 1 and 2 (SPRY1 & SPRY2). Consistent with these 
findings, transcriptional signatures associated with MEK and mTOR activation are repressed 
in human tumors that expressed high levels of EZH2. Given that many of the known 
oncogenes in lung cancer activate these pathways, EZH2 appears to promote tumorigenesis 
through mechanisms that do not involve these canonical pathways, which has important 
mechanistic and therapeutic implications. Some EGFR and KRAS mutant human cancers 
also express high levels of EZH2, but our data in mouse models suggest that EZH2 
expression does not modify the tumorigenesis of strong oncogenic alterations in KRAS. 
However, in some settings these pathways may cooperate. Consistent with this concept, 
DUSP4 has been implicated as a growth suppressor in EGFR-mutant lung adenocarcinoma 
(49) and as a positive activator of ERK in EGFR-mutant lung cancer cell lines (50). A 
unifying model for EZH2-mediated malignant transformation based on these findings could 
be the remodeling of chromatin architecture toward a de-differentiated cell state that 
facilitates proliferative transformation by additional genetic drivers. By further analyzing the 
changes on super-enhancer landscape and the TF connection through CRC, we have 
established the unique signature of EZH2 lung cancers, and distinguished it from other lung 
cancer types, such as KRAS.
Using functional genetic (shRNA) and chemical genetic approaches, we have demonstrated 
the dependency of EZH2-overexpressing human and murine lung cancer models on EZH2. 
Toward pharmacologic target validation, we have created a novel, SAM-competitive 
inhibitor that establishes an evident therapeutic index for targeting EZH2-overexpressing 
tumors in vivo. JQEZ5 demonstrates consistent anti-tumor activity at 75 mg/kg versus 
reported studies of GSK-126 at doses as high as 150 mg/kg (28). We expect the JQEZ5 
chemical probe to be useful to the broader research community, in a manner similar to our 
experience openly distributing probes for BET bromodomains (51). Successful clinical 
translation of targeted lung cancer therapeutics has been facilitated by genomic or 
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immunohistochemical biomarkers. Here, we show that EZH2 is essential for the growth of 
human lung cancer cell lines that express high levels of EZH2, while being dispensable for 
cell lines with lower levels of EZH2. As such, EZH2 expression may be a useful biomarker 
for patient selection or planned stratification in downstream clinical trials. These findings 
support prior work in prostate cancer, where EZH2 was found to be indispensable for cell 
growth in LNCaP-abl cells with higher EZH2 levels, but not in LNCaP cells with lower 
EZH2 levels (43).
EZH2 inhibition has previously been proposed as a therapeutic strategy in NSCLC in the 
context of BRG1 or EGFR mutations (41). This study found that EZH2 inhibitors can 
sensitize NSCLC cells with EGFR or BRG1 mutations to chemotherapy and a combination 
of EZH2 inhibition with Topo II inhibition was proposed. Here, we establish EZH2 
inhibition as an effective single-agent therapy in the defined subset of NSCLC that 
overexpress EZH2 without other known concurrent oncogenic mutations. Still, we anticipate 
that the genetic complexity and tumor heterogeneity that is a common feature lung 
adenocarcinoma will require pairing EZH2 inhibition with other effective therapeutic 
strategies. Pairing epigenomic EZH2 inhibition with oncogene-directed therapy or immune 
checkpoint therapies are appealing concepts.
In sum, this work establishes an oncogenic role for EZH2 deregulation in lung 
adenocarcinoma, creates faithful models of a unique subset of human disease, describes and 
characterizes a novel chemical probe for studying EZH2 function in both xenograft and 
GEM models, and provides the rationale for human clinical investigation.
Methods
Cell culture
H661, H292 and H522 human lung carcinoma cell lines were purchased from and 
authenticated through routine STR analysis and cytogenetic studies by ATCC. H969, H2250 
and H2258 cell lines were a kind gift from Dr. Kenneth Huffman at UT Southwestern 
Medical Center; hTBE cells were a kind gift from Dr. William C. Hahn at Dana-Farber 
Cancer Institute. hTBE cells were received and last authenticated in 2011; all other cells 
were received and last authenticated by standard methods in 2014. Human lung carcinoma 
cell lines were cultured in RPMI-1640/10% FBS/1% penicillin–streptomycin. 293ft cells 
(Invitrogen) were cultured in Dulbecco's Modified Eagle Medium (DMEM)/10% FBS/1% 
penicillin–streptomycin. Fresh murine lung tumor nodules were minced and cultured in 100-
mm dishes with RPMI-1640/10% FBS/1% penicillin–streptomycin. All cells were cultured 
at 37°C in a humidified incubator with 5% CO2.
Western blot
Tissues were lysed in 1× lysis buffer (Cell Signaling Technology, #9803) with protease 
inhibitor cocktail (EMD Biosciences, 539131). Cell lysates were separated using standard 
western blotting procedures, and membranes were probed with the following antibodies: 
mouse monoclonal EZH2 (BD Transduction Laboratories, #612666) at 1:1000; total AKT 
(Cell Signaling Technology, #9272) at 1:2000; total Erk1,2 (Cell Signaling Technology, 
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#4695S) at 1:2000; pAKT antibody (Cell Signaling Technology, #4060S) at 1:1000; 
pERK1,2 (Cell Signaling Technology, #4376S) at 1:1000) all incubated overnight at 4µC. β-
actin-HRP (SIGMA A3854, 1:20000) was used as loading control. Secondary antibody 
Anti-rabbit IgG, HRP-linked Antibody (Cell Signaling 7074, 1:2000) or Anti-mouse IgG, 
HRP-linked Antibody (Cell Signaling 7076, 1:2000) was incubated for 1 hour at room 
temperature. After washing, chemiluminescence was visualized with Western Lightning 
Plus-ECL (PerkinElmer) and exposure onto KODAK BioMax XAR film. Relative 
quantifications were performed using ImageJ software.
Chromatin preparation
Mouse lung tissue was pulverized using a Covaris Tissue Smasher (Model #CP02) following 
the CryoPrep Dry Pulverization Manuel. Lung tissue was smashed 1–2 times on setting 4 in 
the tissueTUBE (Covaris #520071). Approximately 50mg of pulverized lung tissue was 
cross-linked with prewarmed 1% formaldehyde (ThermoScientific #28906 diluted in PBS) 
for 20 minutes at 37°C. The tissue was spun down at 1,000 rpm for 2 min and quenched with 
0.125M glycine in PBS + 0.5% BSA for 20 min at room temperature. It was spun down at 
1,000 rpm for 2 min and washed with PBS + 2× Protease Inhibitor Cocktail (PIC) (Roche 
#11873580001) + 5 mM Sodium Butyrate (Millipore #19-137) and then spun down at 1,000 
rpm for 2 min. The cross-linked tissue was lysed with 390uL ChIP Lysis Buffer (1% SDS, 
10nM EDTA pH8.0, 50mM Tris-HCl pH 8.0, 2× PIC and 5mM Sodium Butyrate) on ice for 
1 hr. The lysate was split into 3 microTUBEs (Covaris #520045) and sheared on the Covaris 
E210 Series with 5% Duty Cycle, 5 Intensity, 200 Cycles per Burst for a total of 27 minutes. 
The sheared chromatin was spun down at 14,000 rpm for 15 min at 4°C. An aliquot of input 
was saved while the remaining chromatin was snap frozen and stored at −80°C. Input was 
brought up to 100ul with TE, 10ug of RNAseA (Roche) added and incubated for 30 minutes 
at 37°C followed by addition of 100ug of Proteinase K (Roche) and incubation at 65°C 
overnight. Input was purified with Qiagen PCR Purification Kit (#28104) and quantified.
Library preparation and ChIP
The prepared chromatin was thawed on ice while 10ug of antibodies against either H3K27ac 
(Abcam #Ab4729) or H3K27me3 (Cell Signaling #CS9733S) was conjugated to a mix of 
magnetic Protein A and Protein G coupled beads (Invitrogen #100.02D and #100.04D, 
respectively) in the presence of 0.5% BSA in PBS with rotation at 4°C for 2 hours. Beads 
were washed 3 times with 0.5%BSA in PBS and either 5ug of chromatin was added to the 
H3K27ac ChIP or 10ug of chromatin was added to the H3K27me3 ChIP and rotated 
overnight at 4°C. The beads were washed 2 times with Tris-based RIPA buffer (0.1% SDS, 
1% Triton X-100, 10mM Tris-HCl pH 7.4, 1mM EDTA pH 8.0, 0.1% Sodium 
Deoxycholate), 2 times with 0.3M NaCl RIPA (0.1% SDS, 1% Triton X-100, 10mM Tris-
HCl pH 7.4, 1mM EDTA pH 8.0, 0.1% Sodium Deoxycholate, 0.3M NaCl), 2 times with 
LiCl Buffer (250mM LiCl, 0.5% NP-40, 0.5% Sodium Deoxycholate, 1mM EDTA pH 8.0, 
10mM Tris-HCl pH 8.0) and 2 times with TE buffer pH 7.6 (Fisher Scientific cat. no. 
BP2474-1). The beads were resuspended in 100uL of TE and RNAseA and PK digested/
reverse crosslinked and purified as described in the chromatin prep. Chromatin libraries 
were prepared with 10–20ng of Input or ChIP’d DNA according to the ThruPLEX-FD Prep 
Kit (Rubicon #R40048) and sequenced by SE75 Next-Seq.
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PRC2 methyltransferase assay
Recombinant five-component PRC2 (EZH2/EED/SUZ12/RBBP4/AEBP2) was co-expressed 
in Sf9 and purified as described (52). PRC2 activity was measured using a radiometric 
Scintillation Proximity Assay (SPA) performed in 384-well OptiPlates (Perkin Elmer). For 
IC50 determination, 2.3 nM PRC2 was incubated for 90 min at RT with 1 uM histone H3 
(21–44)-lys(biotin) (Anaspec), 1.5 uM SAM (NEB), and 500 nM 3H-SAM in 20 uL reaction 
buffer (50 mM Tris pH 8.5, 5 mM DTT, and 0.01% Tween-20) containing compound or 
DMSO. Reactions were quenched with TCA and, following the addition of PVT 
streptavidin-coated SPA beads (Perkin Elmer; 40 uL of 140 ng diluted in PBS), incubated 
for 1 hr at RT. CPM values were measured using the TopCount NXT plate reader. Percent 
activity values were calculated by setting the average background (no-enzyme wells) to 0% 
and the average DMSO wells to 100% activity. Standard deviations were determined from 
four replicate measurements for each compound concentration. Data were analyzed and 
plotted using GraphPad PRISM v6, using the ‘log(inhibitor) vs normalized response –
variable slope’ analysis module to calculate IC50.
For determination of JQEZ5 mechanism of action and Ki values, reactions were carried out 
as described above in the presence of varying concentrations SAM/3H-SAM (at a 1:20 ratio) 
with a fixed concentration of 1 uM histone H3 peptide. Data were analyzed and plotted 
using ‘Enzyme Kinetics –inhibition’ and ‘Enzyme Kinetics – substrate versus velocity’ 
analysis modules in GraphPad PRISM v6.
In vivo studies with JQEZ5
JQEZ5 was dissolved in DMSO and then diluted 1:10 in 10% (2-Hydroxypropyl)-β-
cyclodextrin (Sigma-Aldrich). DMSO (vehicle) was dissolved 1:10 in 10% (2-
Hydroxypropyl)-β-cyclodextrin. Tumor-bearing GEMMs were monitored for onset of 
symptoms (breath distress) and then treated with JQEZ5 for three weeks (75 mg/kg IP 
daily). Tumors were visualized by MRI and tumor volume of the lungs was calculated using 
3D Slicer (53). For xenograft experiments, H661 cells were dissociated into single cells, 
counted and resuspended at 2×106 cells per 250 µl of 1:1 media/matrigel (BD). Eight- to 12-
week-old female Foxn1nu/Foxn1nu (Nude) mice (Harlan) were injected subcutaneously with 
2 × 106 cells in two to three spots on the flanks. Tumors were allowed to grow to an 
approximate size of 200 mm3 (~10 weeks) and the mice were randomized for vehicle (n=3) 
or JQEZ5 administration (n=6, 75 mg/kg/d, i.p.) for 18 days. Tumor growth was measured 
by caliper measurements and tumor volume was calculated by standard methods. All mice 
were housed in pathogen-free animal facilities, and all experiments were performed with the 
approval of the Animal Care and Use Committee at Harvard Medical School and Dana-
Farber Cancer Institute.
Sequencing Data
Sequencing data reported in this paper have been deposited in NCBI's Gene Expression 
Omnibus and are accessible through GEO Series accession number GSE70047.
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Synthesis of small molecule inhibitors
GSK-126, GSK-343 and UNC1999 were directly purchased from Sigma-Aldrich, Inc. The 
structure and purity of these two compounds were further confirmed by NMR and LCMS. 
The detailed syntheses of compound JQEZ5, JQEZ6 and JQEZ23 are described in 
Supplementary Methods.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Statement of Significance
EZH2 overexpression induces murine lung cancers that are similar to human NSCLC 
with high EZH2 expression and low levels of phosphorylated AKT and ERK, implicating 
biomarkers for EZH2 inhibitor sensitivity. Our novel EZH2 inhibitor, JQEZ5, promotes 
regression of these tumors, revealing a potential role for anti-EZH2 therapy in lung 
cancer.
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Figure 1. EZH2 Overexpression Induces Murine Lung Cancer
(A) Schematic depiction of LSL-EZH2 genetically engineered mouse model utilizing 3 
different strategies to express Cre recombinase to induce EZH2 overexpression.
(B) Kaplan–Meier lung cancer-free survival summary plot for Actin-Cre:LSL-EZH2 
transgenic mice (EZH2) versus wildtype mice (WT).
(C) Histology of wildtype lung (top) and EZH2-induced lung adenocarcinomas (bottom) 
Sections stained with hematoxylin and eosin (H&E) or immunostained for Ki-67. Scale 
bar=50µm.
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(D) H&E staining or immunostaining for EZH2, p-AKT, and p-ERK1/2 in EZH2-induced 
mouse lung tumors (top) and KRAS-induced mouse lung tumors (bottom). Scale bar=50µm.
(E) Relative protein expression levels of p-AKT, p-ERK1,2 and EZH2 in normal, EZH2-
induced, and KRAS-induced tumor lung tissues measured by Western blot and quantified 
with ImageJ. n=3 for normal lung and EZH2-induced tumor, n=2 for KRAS-induced tumor.
(F) Indicated mice were sacrificed 6 weeks post Cre-induction for immunostaining for 
EZH2.
(G) Kaplan–Meier lung cancer-free survival summary plot for the indicated mice.
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Figure 2. EZH2-Driven Lung Cancer as a Molecularly Distinct Entity
(A) Heatmap of log2 fold-change (LFC) gene expression in murine EZH2-overexpressing 
(OE) normal lungs (green), KRAS-mutant lung tumors (black), EGFR-mutant lung tumors 
(blue), and EZH2-OE lung tumors (red). All genes were selected across all samples for 
clustering.
(B) Box plot of ssGSEA comparing the enrichment of a MEK (left) and mTOR (right) gene 
sets in human TCGA lung adenocarcinomas with specific driver mutations (KRAS, EGFR, 
unknown) or high EZH2 levels.
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(C) Waterfall plot showing rank-ordered change in H3K27ac signal at SE-containing regions 
between mouse WT lung and EZH2_OE (left), and KRAS and EZH2_OE (right). X-axis 
depicts the LFC in H3K27ac signal. SEs are ranked by LFC in signal with regions gaining 
the most H3K27ac in tumor at the top.
(D) Core transcriptional regulatory circuitry in murine wildtype (WT) and tumor lung 
tissues (EZH2- or KRAS-driven) as defined by ChIP-seq for H3K27ac. Nodes are TFs that 
are associated with an SE. Edges indicate a regulatory interaction between two TFs as 
defined by an enrichment of TF binding motifs in the respective SE.
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Figure 3. EZH2 Overexpression Establishes a Unique and Conserved Super Enhancer-
Associated Transcriptional Landscape
(A) Box plot of RNA-seq expression in units of FPKM of murine genes associated with SEs 
that are gained (1812 genes), unchanged (4421 genes), or lost (432 genes) in tumor versus 
WT lung tissues. Significance was calculated using a two-tailed t test. ** p<2e–4, *** p 
<2e–6
(B) Scatter plot of normalized enrichment score (NES) versus false discovery rate (FDR) q-
value comparing MSigDB curated gene set enrichment in murine tumor versus WT SE-
associated genes. X-axis shows NES for evaluated gene sets. Y-axis shows false FDR q-
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value for each gene set. Gene sets upregulated in tumors have a high positive NES, while 
downregulated gene sets have a negative NES. Dotted line indicates significance cutoff q-
value of 0.05. Red dots indicate PRC2 associated signatures, n = 8.
(C) SE-associated gene set enrichment analysis showing downregulation of EED targets in 
murine tumor versus WT tissues from RNA-seq analysis.
(D) Heatmap of LFC in H3K27ac over H3K27me3 signals at SE-containing regions. Blue 
regions indicate SEs with strong gains of H3K27me3 in tumor versus WT, while red regions 
indicate those with strong losses.
(E) Dot plot of RNA-seq expression in units of log10 FPKM for genes proximal to SE 
regions with a strong gain of H3K27me3 in murine tumor versus WT. Significance was 
calculated with a two-tailed t test. **p<1e–5.
(F) 32 mouse genes proximal to SE regions with strong H3K27me3 gain in EZH2-
overexpressing tumors.
(G) Gene tracks of ChIP-seq signals in units of rpm/bp for H3K27ac and H3K27me3 at the 
DUSP4 locus in either murine WT or tumor lung tissues.
(H) Western blot analysis of lysates prepared from murine normal lung (N-1, N-2 and N-3) 
and lung tumor (T-1, T-2 and T-3) samples.
(I) Box plot of ssGSEA comparing the enrichment of our mouse H3K27me3 gene set in 
human TCGA lung adenocarcinomas with high EZH2 levels and normal lung tissue. The 
H3K27me3 gene set is comprised of the 32 mouse genes proximal to SE regions with strong 
H3K27me3 gain in murine EZH2-overexpressing tumors.
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Figure 4. A Subset of Human NSCLC Cells are Dependent on EZH2 Overexpression
(A) Human NSCLC H661 (left) and H292 (right) cells expressing non-targeting control 
shRNA (NT) or two different shRNAs targeting EZH2 (shEZH2-A and shEZH2-B) were 
analyzed for EZH2 expression by Western blotting.
(B) Western blots comparing EZH2 expression levels between human NSCLC cell lines 
H661 and H292.
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(C–D) Relative cell growth of H661, H522 (C) or H292 (D) cells expressing non-targeting 
control shRNA (NT) or two different shRNAs targeting EZH2 (shEZH2-A and shEZH2-B) 
was measured by MTS assay. Error bars represent S.E.M., n= 3. ** p < 0.001.
(E–F) Human NSCLC cell lines, H661 and H292, infected with lentivirus containing control 
(NT) or shEZH2 (shEZH2-A and shEZH2-B) were subcutaneously injected into the flank of 
nude mice. When the biggest tumor reached approximately 150 mm3, mice were euthanized 
and tumors were quantified relative to shNT tumor size (E) and documented (F). Mean ± 
SEM, n=3/treatment.
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Figure 5. Small Molecule EZH2 Inhibitor Development
(A) Chemical structures of small molecule EZH2 inhibitor, JQEZ5, and negative control 
compound, JQEZ23.
(B) Small molecule inhibitory activity of JQEZ5, JQEZ23, GSK-126 and UNC1999 were 
measured in a five-component PRC2 complex radiometric Scintillation Proximity Assay 
(SPA) using radiolabeled S-adenosyl methionine (SAM).
(C) The IC50 of JQEZ5 as measured with increasing SAM concentrations to confirm its 
SAM competitive binding activity.
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(D) Computational docking model of JQEZ5 binding to EZH2 using reported model.
(E) Biacore SPR sensorgram from single-cycle kinetics runs with four concentrations of the 
PRC2 five component complex. A biotinylated derivative of JQEZ5, JQEZ6, was 
immobilized on streptavidin SPR chip. The affinity (KD) of PRC2 for JQEZ6 was 
determined to be 87 nM.
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Figure 6. JQEZ5 Inhibits Lung Cancer Growth of EZH2 Overexpressed Human Lung Cancer 
Cell
(A) H661 and H292 human lung cancer cells were incubated with increasing concentrations 
of JQEZ5. Cell lysates were prepared and subjected to SDS-PAGE and analysis by Western 
blotting with the indicated antibodies.
(B) Western blots of methylation levels in human lung cancer cell line H661, 72h after 
treatment with increasing concentrations of JQEZ23. H3 is a loading control.
(C) Western blots of methylation levels in H661 human lung cancer cell line after 48 h or 72 
h of treatment with increasing concentrations of JQEZ5. H3 is a loading control.
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(D) H661 and (E) H292 human lung cancer cells were incubated with increasing 
concentrations of JQEZ5 and relative cell growth was assessed by MTS assay. Error bars 
represent SD, n=3.
(F) H661 cells infected with lentivirus containing control (NT) or shEZH2 were incubated 
with increasing concentrations of JQEZ5 and relative cell growth was assessed by MTS 
assay. Error bars represent SD, n=3.
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Figure 7. JQEZ5 Inhibits Lung Cancer Growth In Vivo
(A–B) MRI scans of individual tumor-bearing Actin-Cre;LSL-EZH2 mice (t=0) and after 1–
3 weeks of treatment with JQEZ5 at 75mpk, daily. Lung tumor is indicated by the red circle. 
H, Heart.
(C) Quantification of relative tumor volume of mouse lungs based on MRIs using 3D Slicer. 
Relative tumor volume was compared before and after 3 weeks of JQEZ5 treatment (mean 
± SEM, n=2).
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(D) Tumor-bearing Actin-Cre;LSL-EZH2 mice were untreated or treated with JQEZ5 at 
75mpk for three weeks. Lung sections were prepared and immunostained for H3K27me3. 
Bar represents 50µm.
(E) Nude mice were injected subcutaneously with 2×106 H661 human NSCLC cells. When 
tumors reached ~200 mm3, mice were randomized and treated with vehicle or JQEZ5 (75 
mg/kg/d, i.p.) for 18 days. Western blots analysis was performed on tumors following either 
vehicle or JQEZ5 treatment for 18 days.
(F) Western blots analysis of lung tissue from mice after 18 days of treatment with vehicle or 
JQEZ5 at 75 mpk.
(G) Tumor volume from mouse xenograft model of human lung cancer was measured by 
caliper (mean ± SEM, n=3/vehicle, n=6/JQEZ5).
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